GLP-1s: Existential Threat to Arthroplasty Volume
- 6 days ago
- 1 min read
GLP-1s appear to be more than weight loss drugs, potentially offering direct joint protection and dramatically reducing surgical risk.
By the numbers
Recent research demonstrates significant clinical benefits across multiple measures:
40% of obese patients with known hip arthritis prescribed a GLP-1 showed a reduced risk of hip replacement within one year, based on data from 239,000+ patients.
25% of obese patients with known knee arthritis on a GLP-1 demonstrated a reduced risk of knee replacement within one year.
1.0% versus 1.8% represents the prosthetic joint infection rates in morbidly obese patients on GLP-1s compared to those not on them – nearly half the risk. Readmissions also dropped from 8.9% to 5.3%.
Bottom line
As GLP-1 adoption grows, orthopedic programs should expect meaningful declines in both primary arthroplasty volume and post-operative complications.
Comments